DEA Wants to Schedule Concentrated 7-OH Kratom Like Heroin. The Comment Window Closes Today.

Today is the last day to weigh in before the federal government decides how to treat one of the fastest-growing products in the supplement and vape-shop aisle. HHS’s public comment period on DEA’s proposal to temporarily place concentrated 7-hydroxymitragynine — 7-OH, the compound behind the gummies, shots, and dissolvable strips increasingly marketed as “kratom extract” — into Schedule I closes today, July 31. If the comment period doesn’t change DEA’s course, the Attorney General is positioned to issue a formal two-year temporary scheduling order as early as August 5.

The rule is narrower than most of the coverage of it, and that distinction is going to matter to a lot of people who think this is about to make their kratom illegal.

DEA’s proposal targets 7-OH specifically above a defined concentration threshold — 0.050% by dry weight in raw botanical material, or 0.050%/1.00mg in processed extracts and edibles — plus three related synthetic or lab-modified compounds (mitragynine pseudoindoxyl, and two designated only as MGM-15 and MGM-16). It does not touch traditional, low-concentration kratom leaf or tea, the form millions of Americans have used for years to manage chronic pain, opioid withdrawal symptoms, or anxiety without a prescription. HHS and FDA both publicly backed the action, framing it as closing a loophole that let manufacturers chemically concentrate a minor, mildly active compound in raw kratom into something with opioid-like potency and abuse potential — closer, pharmacologically, to a synthetic opioid than to the plant it’s marketed alongside.

That’s a real and defensible distinction on paper. In practice, it’s the kind of line regulators draw that retailers, and the users who’ve come to depend on 7-OH products specifically, don’t always respect at the point of sale. Someone using a high-concentration 7-OH shot to self-manage opioid withdrawal because they can’t access buprenorphine, or because they’re trying to avoid returning to a drug that’s more likely to kill them, is not the same person as someone drinking kratom tea for energy — but both are about to watch the same regulatory hammer fall on very different-looking products sold three feet apart on the same shelf. If the concentrated version disappears from that shelf on August 5 and nothing replaces it for the people actually using it to stay off something stronger, the harm-reduction math on this rule will look very different in six months than it does in the DEA’s press release today.